EUVIMEDEUVIMED entdecken
Crossref

1674-P: Trends in Antidiabetic Medication Use among California Medicare Beneficiaries, 2013–2022

JIAHUI DAI, WENJUN FAN, YUXI SHI, MARIA M. CORRADA, ANNIE RO, SPERO M. MANSON, JOAN OCONNELL, LUOHUA JIANG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1674-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JIAHUI DAI und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Utilization patterns of anti-diabetic medications among U.S. older adults with diabetes remain incompletely characterized. This study aimed to examine temporal trends in anti-diabetic medication use from 2013-2022 among Medicare beneficiaries aged≥65 with diabetes, with a primary focus on California.

Methods

Data was from CMS Medicare Beneficiary Summary File (2013-2022) covering 21 U.S. states, with California analyzed separately. This descriptive study included adults aged≥65 with diabetes who had 11-12 months Part A&B fee-for-service and Part D coverage each year. We examined the use of traditional anti-diabetic medications: metformin, sulfonylureas, insulin, thiazolidinediones, fixed-dose combinations, and newer agents: sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i). Annual utilization rate for a medication class was defined as the proportion of adults filling 1+ prescriptions in that class during the year.

Results

An average of 94,366 California adults with diabetes were identified annually. From 2013-2022, use of metformin, SGLT2i, and GLP-1 RAs increased, while insulin, sulfonylureas, fix-dose combinations, and DPP-4i declined (Figure 1).

Conclusion

Our study demonstrates a substantial increase in use of newer anti-diabetic medications among U.S. older adults, reflecting their growing adoption in clinical practice. Disclosure J. Dai: None. W. Fan: None. Y. Shi: None. M.M. Corrada: None. A. Ro: None. S.M. Manson: None. J. OConnell: None. L. Jiang: None.

Zitieren

APA

DAI, J., FAN, W., SHI, Y., CORRADA, M. M., RO, A., MANSON, S. M., OCONNELL, J., & JIANG, L. (2026). 1674-P: Trends in Antidiabetic Medication Use among California Medicare Beneficiaries, 2013–2022. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1674-p

Vancouver

DAI J, FAN W, SHI Y, CORRADA MM, RO A, MANSON SM, et al. 1674-P: Trends in Antidiabetic Medication Use among California Medicare Beneficiaries, 2013–2022. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1674-p

BibTeX
@article{DAI2026,
  author = {DAI, JIAHUI and FAN, WENJUN and SHI, YUXI and CORRADA, MARIA M. and RO, ANNIE and MANSON, SPERO M. and OCONNELL, JOAN and JIANG, LUOHUA},
  title = {1674-P: Trends in Antidiabetic Medication Use among California Medicare Beneficiaries, 2013–2022},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1674-p}
}
Kostenlos starten →